ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Lineus Medical Receives Japanese Patent for SafeBreak® Vascular and United States Patent for BVAD

By: PRLog

FAYETTEVILLE, Ark. - Aug. 24, 2022 - PRLog -- Lineus Medical continues to expand its patent portfolio with the issuance of two new patents. The first issued patent was a Japanese Utility Patent (JP7095097) for SafeBreak® Vascular, a break-away medical device that helps protect peripheral IV lines. The second issued patent was a US utility patent for a dual lumen peripheral IV catheter, BVAD (Bifurcated Venous Access Device). Lineus Medical's patent portfolio has grown to nine issued patents from various countries across the world, with more patents pending.

SafeBreak Vascular is a first of its kind, FDA cleared breakaway device designed to remove harmful forces from peripheral IV (PIV) lines by intentionally separating when damaging levels of force are applied to the IV line. By preventing harmful IV line tension from reaching the catheter, SafeBreak Vascular reduces mechanical PIV complications requiring an IV restart.

BVAD, the second device in the company's pipeline, is a dual lumen peripheral IV catheter designed to allow uncontaminated blood draws from a dedicated secondary lumen while allowing normal infusions through the primary lumen. BVAD furthers the company's goal that every patient should have one catheter and one needlestick per hospitalization, and intends to provide value and efficiency to nurses and hospitals.

Vance Clement, CEO of Lineus Medical, said, "The issuance of both the Japanese patent for SafeBreak Vascular and our US patent for BVAD are significant milestones as we expand our patent portfolio and look to expand internationally. These patents are critical steps in our mission to remove the pains associated with medical lines, not just in the US, but globally."

Spencer Jones, Founder and Chief Technology Officer, commented, "Japan is the second largest medical device market in the world, so securing patent protection for SafeBreak Vascular in this market captures enormous enterprise value for our organization. BVAD has already been granted patent protection in several international markets and obtaining a patent in the US is another invaluable addition to our portfolio. Consistent innovation is crucial for emerging companies like Lineus Medical, and protecting those ideas is paramount."

ABOUT LINEUS MEDICAL
Lineus Medical is the developer of vascular access products that are designed to improve the patient experience, make nurse's jobs easier and lower the overall cost of healthcare. Learn more at www.lineusmed.com and follow us on LinkedIn,  Twitter, or Instagram. BVAD is not 510(k) cleared and not yet for sale.

Contact
Vance Clement
***@lineusmed.com

Photos: (Click photo to enlarge)

Lineus Medical Logo BVAD: Dual Lumen Peripheral IV Catheter SafeBreak Vascular Spencer Jones, Founder and CTO of Linues Medical Vance Clement, CEO of Lineus Medical

Read Full Story - Lineus Medical Receives Japanese Patent for SafeBreak® Vascular and United States Patent for BVAD | More news from this source

Press release distribution by PRLog

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.